Garret A. FitzGerald

Garret A. FitzGerald's AcademicInfluence.com Rankings

Philosophy

#2618

World Rank

#4419

Historical Rank

Logic

#674

World Rank

#1175

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Garret A. FitzGerald Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Garret Adare FitzGerald is an Irish physician. He is professor of in translational medicine and Therapeutics and chair of the department of pharmacology at the Perelman School of Medicine of the University of Pennsylvania. He researches aspects of cardiology, pharmacology, translational medicine, and chronobiology.

(See a Problem?)

Garret A. FitzGerald's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients (1994) (3667)
Prostaglandins and Inflammation (2011) (2543)
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials (2013) (1418)
Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. (1999) (1329)
Platelet activation in unstable coronary disease. (1986) (1223)
Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis (2007) (1084)
A Functional Genomics Strategy Reveals Rora as a Component of the Mammalian Circadian Clock (2004) (1009)
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. (2005) (987)
BMAL1 and CLOCK, Two Essential Components of the Circadian Clock, Are Involved in Glucose Homeostasis (2004) (958)
Oxidative Stress and Cardiovascular Injury: Part I: Basic Mechanisms and In Vivo Monitoring of ROS (2003) (915)
Coxibs and cardiovascular disease. (2004) (912)
The coxibs, selective inhibitors of cyclooxygenase-2. (2001) (823)
Role of Prostacyclin in the Cardiovascular Response to Thromboxane A2 (2002) (801)
Oxidative stress and cardiovascular injury: Part II: animal and human studies. (2003) (787)
Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. (2001) (660)
Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? (2005) (653)
Understanding multicellular function and disease with human tissue-specific networks (2015) (653)
Modulation of oxidant stress in vivo in chronic cigarette smokers. (1996) (641)
Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. (1999) (627)
Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment (1991) (583)
Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. (1984) (571)
Modulation of monocyte-endothelial cell interactions by platelet microparticles. (1998) (555)
Genetic and pharmacological analysis of prostanoid receptor function. (2001) (531)
Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice (1998) (526)
Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. (1983) (520)
Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. (1997) (495)
COX-2 and beyond: approaches to prostaglandin inhibition in human disease (2003) (491)
Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. (1988) (489)
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison (2006) (484)
Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. (1997) (475)
Regulation of CLOCK and MOP4 by Nuclear Hormone Receptors in the Vasculature A Humoral Mechanism to Reset a Peripheral Clock (2001) (465)
COX-2-Derived Prostacyclin Confers Atheroprotection on Female Mice (2004) (427)
In vivo indexes of platelet and vascular function during fish-oil administration in patients with atherosclerosis. (1986) (425)
Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. (1987) (421)
Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. (2004) (416)
Concept, Design and Implementation of a Cardiovascular Gene-Centric 50 K SNP Array for Large-Scale Genomic Association Studies (2008) (416)
Increased F2‐isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo (1998) (414)
The antihypertensive effects of fish oil. A controlled study of polyunsaturated fatty acid supplements in essential hypertension. (1989) (411)
Enzymes and Receptors of Prostaglandin Pathways with Arachidonic Acid-derived Versus Eicosapentaenoic Acid-derived Substrates and Products*♦ (2007) (397)
Isoprostanes: Formation, Analysis and Use As Indices of Lipid Peroxidation in Vivo * (1999) (395)
Platelet-active drugs : the relationships among dose, effectiveness, and side effects. (2004) (390)
Obesity in mice with adipocyte-specific deletion of clock component Arntl (2012) (369)
Increased 8,12‐iso‐iPF2α‐VI in Alzheimer's disease: Correlation of a noninvasive index of lipid peroxidation with disease severity (2000) (369)
Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man. (1995) (368)
Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. (1991) (359)
Localization of distinct F2-isoprostanes in human atherosclerotic lesions. (1997) (357)
Circadian clock proteins regulate neuronal redox homeostasis and neurodegeneration. (2013) (347)
Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. (2006) (343)
Rhythmicity of the intestinal microbiota is regulated by gender and the host circadian clock (2015) (338)
Circadian variation of blood pressure and the vascular response to asynchronous stress (2007) (330)
Indices of lipid peroxidation in vivo: strengths and limitations. (2000) (306)
Cloning and expression of a cDNA for the human prostaglandin E receptor EP1 subtype. (1993) (304)
Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma. (2003) (302)
Increased formation of distinct F2 isoprostanes in hypercholesterolemia. (1998) (294)
Oxidative stress. Introduction. (2001) (291)
Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. (1991) (285)
11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. (1986) (283)
Effects of vitamin E on lipid peroxidation in healthy persons. (2001) (282)
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. (2012) (282)
Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2alpha-III, an index of oxidant stress. (1998) (277)
Decreased prostacyclin biosynthesis preceding the clinical manifestation of pregnancy-induced hypertension. (1987) (262)
Alcohol-induced generation of lipid peroxidation products in humans. (1999) (253)
Estimated rate of thromboxane secretion into the circulation of normal humans. (1986) (247)
Arachidonic Acid in Platelet Microparticles Up-regulates Cyclooxygenase-2-dependent Prostaglandin Formation via a Protein Kinase C/Mitogen-activated Protein Kinase-dependent Pathway* (1999) (246)
Absence of 12/15-Lipoxygenase Expression Decreases Lipid Peroxidation and Atherogenesis in Apolipoprotein E—Deficient Mice (2001) (246)
Cylooxygenase-dependent Formation of the Isoprostane, 8-Epi Prostaglandin F2α(*) (1995) (245)
Oxidative stress and smoking-induced vascular injury. (2003) (245)
Effect of regulated expression of human cyclooxygenase isoforms on eicosanoid and isoeicosanoid production in inflammation. (2000) (245)
Network Features of the Mammalian Circadian Clock (2009) (242)
Cyclooxygenases and prostaglandins: shaping up the immune response. (2002) (238)
Prostaglandin D2 Inhibits Hair Growth and Is Elevated in Bald Scalp of Men with Androgenetic Alopecia (2012) (230)
Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice (2001) (227)
Timing of expression of the core clock gene Bmal1 influences its effects on aging and survival (2016) (227)
Circadian control of innate immunity in macrophages by miR-155 targeting Bmal1 (2015) (220)
Thromboxane A2 in Vasotonic Angina Pectoris (1981) (219)
Local Amplification of Platelet Function by 8-Epi Prostaglandin F2α Is Not Mediated by Thromboxane Receptor Isoforms* (1996) (218)
Developmental expression of functional cyclooxygenases in zebrafish (2002) (210)
Emotion recollected in tranquility: lessons learned from the COX-2 saga. (2010) (208)
Paired analysis of urinary thromboxane B2 metabolites in humans. (1987) (208)
Simulation-based comprehensive benchmarking of RNA-seq aligners (2016) (208)
Thromboxane A2 synthesis in pregnancy-induced hypertension (1990) (204)
Vascular COX-2 Modulates Blood Pressure and Thrombosis in Mice (2012) (203)
Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis (2006) (202)
Histone Acetyltransferase-dependent Chromatin Remodeling and the Vascular Clock* (2004) (201)
Increased Formation of the Isoprostanes IPF2α-I and 8-Epi-Prostaglandin F2α in Acute Coronary Angioplasty (1997) (199)
Causal effects of body mass index on cardiometabolic traits and events: a Mendelian randomization analysis. (2014) (198)
IPF2α-I: An index of lipid peroxidation in humans (1998) (198)
Cyclooxygenases, Thromboxane, and Atherosclerosis: Plaque Destabilization by Cyclooxygenase-2 Inhibition Combined With Thromboxane Receptor Antagonism (2005) (194)
Biomarkers of oxidative stress study III. Effects of the nonsteroidal anti-inflammatory agents indomethacin and meclofenamic acid on measurements of oxidative products of lipids in CCl4 poisoning. (2005) (193)
Generation of 8-epiprostaglandin F2alpha by human monocytes. Discriminate production by reactive oxygen species and prostaglandin endoperoxide synthase-2. (1996) (191)
Drug Resistance and Pseudoresistance: An Unintended Consequence of Enteric Coating Aspirin (2013) (189)
COX-2 inhibitors and cardiovascular risk. (2007) (188)
Nicotine effects on eicosanoid formation and hemostatic function: comparison of transdermal nicotine and cigarette smoking. (1993) (188)
PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses (2015) (186)
Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator. (1989) (186)
The isoprostanes in biology and medicine (2001) (181)
Cardiovascular Responses to the Isoprostanes iPF2α-III and iPE2-III Are Mediated via the Thromboxane A2 Receptor In Vivo (2000) (180)
Molecular cloning, primary structure, and expression of the human platelet/erythroleukemia cell 12-lipoxygenase. (1990) (176)
Quantitative high performance liquid chromatography/tandem mass spectrometric analysis of the four classes of F(2)-isoprostanes in human urine. (1999) (175)
Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo. (1989) (171)
Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. (2001) (170)
Prostaglandin I2 Analogs Inhibit Proinflammatory Cytokine Production and T Cell Stimulatory Function of Dendritic Cells1 (2007) (165)
The response to thromboxane A2 analogues in human platelets. Discrimination of two binding sites linked to distinct effector systems. (1990) (159)
Endogenous biosynthesis of arachidonic acid epoxides in humans: increased formation in pregnancy-induced hypertension. (1990) (157)
The Human Thromboxane A2 Receptor α Isoform (TPα) Functionally Couples to the G Proteins Gq and G11 In Vivo and is Activated by the Isoprostane 8-epi Prostaglandin F2α (1997) (154)
Gene-centric meta-analysis in 87,736 individuals of European ancestry identifies multiple blood-pressure-related loci. (2014) (150)
Circadian Clocks and Vascular Function (2010) (150)
Platelet activation by superoxide anion and hydroxyl radicals intrinsically generated by platelets that had undergone anoxia and then reoxygenated. (1997) (148)
Guidelines for Genome-Scale Analysis of Biological Rhythms (2017) (146)
Loci influencing blood pressure identified using a cardiovascular gene-centric array. (2013) (145)
Bioinformatic Analysis of Circadian Gene Oscillation in Mouse Aorta (2005) (145)
Radioimmunoassay of 11-dehydrothromboxane B2 in human plasma and urine. (1987) (145)
Platelet and vascular function during coronary thrombolysis with tissue-type plasminogen activator. (1989) (143)
Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. (1999) (143)
Nomenclature of isoprostanes: a proposal. (1997) (142)
Prostacyclin protects against elevated blood pressure and cardiac fibrosis. (2005) (142)
Misguided drug advice for COVID-19 (2020) (140)
Differential Signaling by the Thromboxane Receptor Isoforms via the Novel GTP-binding Protein, Gh * (1999) (140)
Ablation of Cyclooxygenase-2 in Forebrain Neurons is Neuroprotective and Dampens Brain Inflammation after Status Epilepticus (2011) (138)
Phosphorylation of the Thromboxane Receptor α, the Predominant Isoform Expressed in Human Platelets* (1999) (138)
Microsomal Prostaglandin E Synthase-1 Deletion Suppresses Oxidative Stress and Angiotensin II–Induced Abdominal Aortic Aneurysm Formation (2008) (136)
Genetic Components of the Circadian Clock Regulate Thrombogenesis In Vivo (2008) (135)
Microbes vs. chemistry in the origin of the anaerobic gut lumen (2018) (135)
8-epi PGF2 alpha generation during coronary reperfusion. A potential quantitative marker of oxidant stress in vivo. (1997) (135)
The biochemical pharmacology of thromboxane synthase inhibition in man. (1985) (134)
COX2 in CNS neural cells mediates mechanical inflammatory pain hypersensitivity in mice. (2009) (134)
Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. (2006) (134)
Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. (2011) (133)
Mechanisms of Cellular Activation by Platelet Microparticles (1999) (133)
COX-2-derived prostacyclin protects against bleomycin-induced pulmonary fibrosis. (2006) (129)
Dosing time matters (2019) (128)
Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase. (1986) (128)
Cyclooxygenase‐Dependent Formation of the Isoprostane 8‐EPI Prostaglandin F2α a (1994) (127)
Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations. (2002) (127)
Analysis of the Zebrafish Proteome during Embryonic Development*S (2008) (126)
Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells (2016) (125)
Iron-dependent human platelet activation and hydroxyl radical formation: involvement of protein kinase C. (1999) (125)
Oral delivery of anticoagulant doses of heparin. A randomized, double-blind, controlled study in humans. (1998) (124)
Increased thromboxane biosynthesis in normal pregnancy is mainly derived from platelets. (1987) (124)
The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. (2008) (122)
Long-lived enzymatic metabolites of thromboxane B2 in the human circulation. (1986) (121)
Enhanced lipid peroxidation in patients positive for antiphospholipid antibodies. (1997) (120)
Angioplasty increases coronary sinus F2-isoprostane formation: evidence for in vivo oxidative stress during PTCA. (2001) (120)
Parecoxib, valdecoxib, and cardiovascular risk. (2005) (118)
Interruption of Vascular Thrombus Formation and Vascular Lesion Formation by Dietary n‐3 Fatt Acids in Fish Oil in Nonhuman Primates (1993) (118)
Peripheral circadian clocks in the vasculature. (2007) (117)
Reduction of Isoprostanes and Regression of Advanced Atherosclerosis by Apolipoprotein E* (2001) (117)
The isoprostanes: a perspective. (1997) (114)
COX-2–Derived Prostacyclin Modulates Vascular Remodeling (2005) (113)
Prostaglandin F2α (PGF2α) and the Isoprostane, 8,12-iso-Isoprostane F2α-III, Induce Cardiomyocyte Hypertrophy (1998) (113)
Measurement of renal and non-renal eicosanoid synthesis. (1986) (112)
Inhibition of clot lysis and decreased binding of tissue-type plasminogen activator as a consequence of clot retraction. (1992) (112)
F2-isoprostanes as indices of lipid peroxidation in inflammatory diseases. (2004) (107)
Combined Administration of Aspirin and a Specific Thrombin Inhibitor in Man (1991) (104)
Regulation of amyloid-β dynamics and pathology by the circadian clock (2018) (104)
Functional characterization of the ocular prostaglandin f2alpha (PGF2alpha) receptor. Activation by the isoprostane, 12-iso-PGF2alpha. (1997) (103)
Enhanced lipid peroxidation in hepatic cirrhosis. (1998) (103)
Biosynthesis of thromboxane in patients with systemic sclerosis and Raynaud's phenomenon. (1986) (99)
PharmGKB summary: ibuprofen pathways (2015) (99)
Cardiovascular hazard and non-steroidal anti-inflammatory drugs. (2005) (98)
Directed Vascular Expression of Human Cysteinyl Leukotriene 2 Receptor Modulates Endothelial Permeability and Systemic Blood Pressure (2004) (97)
Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective role in ethanol associated liver injury (2017) (96)
Identification of a Novel Prostaglandin Reductase Reveals the Involvement of Prostaglandin E2 Catabolism in Regulation of Peroxisome Proliferator-activated Receptor γ Activation* (2007) (96)
Thromboxane synthesis and action within the kidney. (1992) (96)
The Cardiovascular Pharmacology of Nonsteroidal Anti-Inflammatory Drugs. (2017) (95)
Tumor cell-intrinsic EPHA2 suppresses anti-tumor immunity by regulating PTGS2 (COX-2). (2019) (95)
Reduced Nitric Oxide Causes Age-Associated Impairment of Circadian Rhythmicity (2008) (95)
Increased formation of the isoprostanes IPF2alpha-I and 8-epi-prostaglandin F2alpha in acute coronary angioplasty: evidence for oxidant stress during coronary reperfusion in humans. (1997) (93)
Rapid, Agonist-dependent Phosphorylation in Vivo of Human Thromboxane Receptor Isoforms (1997) (92)
Point mutation in the seventh hydrophobic domain of the human thromboxane A2 receptor allows discrimination between agonist and antagonist binding sites. (1993) (92)
Increased excretion of leukotriene E4 during aspirin-induced asthma. (1992) (92)
COVID-19, microangiopathy, hemostatic activation, and complement. (2020) (91)
Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation in vivo. (1986) (91)
Prostaglandin endoperoxides modulate the response to thromboxane synthase inhibition during coronary thrombosis. (1988) (90)
The role of clock genes in pharmacology. (2010) (89)
Internalization and Sequestration of the Human Prostacyclin Receptor* (2000) (88)
Role of prostacyclin versus peroxisome proliferator-activated receptor beta receptors in prostacyclin sensing by lung fibroblasts. (2006) (88)
Microsomal Prostaglandin E2 Synthase-1 Modulates the Response to Vascular Injury (2011) (88)
Characterization of human 12-lipoxygenase genes. (1992) (87)
Circadian control of lung inflammation in influenza infection (2018) (86)
Prostaglandin I2 analogs inhibit Th1 and Th2 effector cytokine production by CD4 T cells (2007) (85)
Identification of Two Major F2 Isoprostanes, 8,12-Iso- and 5-epi-8,12-Iso-isoprostane F2α-VI, in Human Urine* (1998) (84)
Bioactive products formed in humans from fish oils1[S] (2015) (80)
Fibrinogen β-Chain Tyrosine Nitration Is a Prothrombotic Risk Factor* (2008) (79)
Effect of the Pl(A2) alloantigen on the function of beta(3)-integrins in platelets. (2001) (79)
Anticipating change in drug development: the emerging era of translational medicine and therapeutics (2005) (79)
COX-2–Dependent Cardiac Failure in Gh/tTG Transgenic Mice (2003) (79)
Prostaglandin F2α elevates blood pressure and promotes atherosclerosis (2009) (79)
Prostaglandin endoperoxide/thromboxane A2 receptor desensitization. Cross-talk with adenylate cyclase in human platelets. (1990) (78)
Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo. (2000) (78)
Prostaglandin I2-IP Signaling Blocks Allergic Pulmonary Inflammation by Preventing Recruitment of CD4+ Th2 Cells into the Airways in a Mouse Model of Asthma1 (2007) (78)
Neurofurans, Novel Indices of Oxidant Stress Derived from Docosahexaenoic Acid* (2008) (78)
Timing the Microbes: The Circadian Rhythm of the Gut Microbiome (2017) (77)
Predominance of cyclooxygenase 1 over cyclooxygenase 2 in the generation of proinflammatory prostaglandins in autoantibody-driven K/BxN serum-transfer arthritis. (2008) (77)
Endogenous biosynthesis of thromboxane and prostacyclin in 2 distinct murine models of atherosclerosis. (2000) (77)
Regulation of thromboxane receptor activation in human platelets. (1989) (76)
Genetic model of selective COX2 inhibition reveals novel heterodimer signaling (2006) (75)
Tetranor PGDM, an Abundant Urinary Metabolite Reflects Biosynthesis of Prostaglandin D2 in Mice and Humans* (2008) (74)
Ongoing prothrombotic state in patients with antiphospholipid antibodies: a role for increased lipid peroxidation. (1999) (74)
Heterogeneity of prostaglandin H2/thromboxane A2 receptors: distinct subtypes mediate vascular smooth muscle contraction and platelet aggregation. (1991) (73)
Eicosenoid biosynthesis and platelet function with advancing age. (1986) (73)
The effects of organic nitrates on prostacyclin biosynthesis and platelet function in humans. (1984) (73)
Endogenous biosynthesis of prostacyclin during cardiac catheterization and angiography in man. (1985) (73)
Prostaglandin D2 inhibits wound-induced hair follicle neogenesis through the receptor, Gpr44 (2012) (72)
Inhibition of advanced glycation endproduct formation by acetaldehyde: role in the cardioprotective effect of ethanol. (1999) (72)
Phosphorylation of the Prostacyclin Receptor during Homologous Desensitization (1998) (72)
Eicosanoid forming enzyme mRNA in human tissues. Analysis by quantitative polymerase chain reaction. (1991) (70)
Agonist-dependent Phosphorylation of an Epitope-tagged Human Prostacyclin Receptor* (1996) (70)
Terms and Conditions: Semantic Complexity and Aspirin Resistance (2004) (68)
Bidirectional interactions between indomethacin and the murine intestinal microbiota (2015) (68)
Differential impact of prostaglandin H synthase 1 knockdown on platelets and parturition. (2005) (68)
IPF2alpha-I: an index of lipid peroxidation in humans. (1998) (66)
Selective and nonselective inhibition of thromboxane formation (1984) (66)
A Pilot Characterization of the Human Chronobiome (2017) (65)
Differential impairment of aspirin-dependent platelet cyclooxygenase acetylation by nonsteroidal antiinflammatory drugs (2014) (64)
8‐Epi PGF2α: specific analysis of an isoeicosanoid as an index of oxidant stress in vivo (2003) (64)
The human thromboxane A2 receptor alpha isoform (TP alpha) functionally couples to the G proteins Gq and G11 in vivo and is activated by the isoprostane 8-epi prostaglandin F2 alpha. (1997) (64)
Dietary α-linolenic acid diminishes experimental atherogenesis and restricts T cell-driven inflammation (2011) (64)
Phosphorylation and regulated expression of the human thromboxane A2 receptor. (1994) (64)
Activation of nuclear receptors by prostaglandins. (2003) (64)
EBP, a Program for Protein Identification Using Multiple Tandem Mass Spectrometry Datasets*S (2007) (63)
Prostacyclin and prostaglandin E1: molecular mechanisms and therapeutic utility. (1991) (63)
Effects of fish oil supplementation in the third trimester of pregnancy on prostacyclin and thromboxane production. (1993) (63)
Niacin and biosynthesis of PGD₂by platelet COX-1 in mice and humans. (2012) (61)
Two polymorphisms in the human lipoprotein lipase (LPL) gene. (1987) (60)
Cyclo-oxygenase products and atherothrombosis. (2000) (60)
Targeted Cyclooxygenase Gene (Ptgs) Exchange Reveals Discriminant Isoform Functionality* (2007) (60)
Human prostacyclin receptor. (2002) (60)
Antihypertensive effects of fish oil. (1989) (60)
Targeted Deletions of Cyclooxygenase-2 and Atherogenesis in Mice (2010) (59)
No evidence for lipid peroxidation in severe preeclampsia. (2001) (59)
Genetic Models Reveal cis and trans Immune-Regulatory Activities for lincRNA-Cox2. (2018) (58)
Thromboxane A2 in vasotonic angina pectoris: evidence from direct measurements and inhibitor trials. (1981) (58)
Circadian Clocks and Metabolism: Implications for Microbiome and Aging. (2017) (58)
Directed vascular expression of the thromboxane A2 receptor results in intrauterine growth retardation (2000) (56)
Noninvasive assessment of the role of cyclooxygenases in cardiovascular health: a detailed HPLC/MS/MS method. (2007) (56)
Cyclooxygenase inhibition, platelet function, and metabolite formation during chronic sulfinpyrazone dosing (1985) (56)
Effects of dietary fat content, saturated fatty acids, and fish oil on eicosanoid production and hemostatic parameters in normal men. (1994) (54)
Cellular activation by thromboxane A2 and other eicosanoids. (1993) (53)
Selective inhibitors of cyclooxygenase-2: a growing class of anti-inflammatory drugs. (2001) (53)
Eicosanoids and isoeicosanoids: indices of cellular function and oxidant stress. (1998) (53)
Peripheral Circadian Clock Rhythmicity Is Retained in the Absence of Adrenergic Signaling (2007) (52)
Novel Eicosapentaenoic Acid-derived F3-isoprostanes as Biomarkers of Lipid Peroxidation* (2009) (52)
Localization of Distinct F 2 -Isoprostanes in Human Atherosclerotic Lesions (1997) (51)
Effects of low-dose aspirin on endogenous eicosanoid formation in normal and atherosclerotic men. (1988) (51)
Antimitogenic effects of HDL and APOE mediated by Cox-2-dependent IP activation. (2004) (50)
Central and peripheral clocks in cardiovascular and metabolic function (2006) (50)
Disruption of the 5-lipoxygenase pathway attenuates atherogenesis consequent to COX-2 deletion in mice (2012) (49)
Time for nonaddictive relief of pain (2017) (48)
Reopening schools during COVID-19 (2020) (48)
COX-2 in play at the AHA and the FDA. (2007) (48)
Thromboxane biosynthesis in allergen-induced bronchospasm. Evidence for platelet activation. (1989) (48)
Signaling through the Prostaglandin I2 Receptor IP Protects against Respiratory Syncytial Virus-Induced Illness (2004) (48)
Cyclooxygenase-2 in Endothelial and Vascular Smooth Muscle Cells Restrains Atherogenesis in Hyperlipidemic Mice (2014) (48)
Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin (1992) (47)
Cyclooxygenase Inhibition: Pain, Inflammation, and the Cardiovascular System (2017) (47)
COX in a crystal ball: current status and future promise of prostaglandin research. (2001) (47)
Molecular clocks in pharmacology. (2013) (45)
Eicosanoid biosynthesis in human cardiovascular disease. (1987) (45)
Cell Selective Cardiovascular Biology of Microsomal Prostaglandin E Synthase-1 (2013) (44)
Prostaglandin F2alpha (PGF2alpha) and the isoprostane, 8, 12-iso-isoprostane F2alpha-III, induce cardiomyocyte hypertrophy. Differential activation of downstream signaling pathways. (1998) (44)
Niacin, an old drug with a new twist (2013) (44)
Immunotargeting of glucose oxidase to endothelium in vivo causes oxidative vascular injury in the lungs. (2000) (44)
Eicosanoids and the vascular endothelium. (2006) (44)
Deletion of cyclooxygenase 2 in mouse mammary epithelial cells delays breast cancer onset through augmentation of type 1 immune responses in tumors. (2011) (43)
Vitamin E reduces monocyte tissue factor expression in cirrhotic patients. (1999) (43)
Total synthesis of a novel isoprostane IPF2α-I and its identification in biological fluids (1996) (43)
Prostaglandin E Synthases in Zebrafish (2004) (42)
The cyclooxygenase-1/mPGES-1/endothelial prostaglandin EP4 receptor pathway constrains myocardial ischemia-reperfusion injury (2019) (42)
Dietary fish oil accelerates the response to coronary thrombolysis with tissue-type plasminogen activator. Evidence for a modest platelet inhibitory effect in vivo. (1990) (42)
Ticlopidine in unstable angina. A more expensive aspirin? (1990) (42)
WAVECLOCK: wavelet analysis of circadian oscillation (2008) (42)
COX-2, the dominant source of prostacyclin (2013) (42)
Effects of selective COX-2 inhibition on allergen-induced bronchoconstriction and airway inflammation in asthma. (2014) (42)
COX-2 inhibitors and the cardiovascular system. (2001) (41)
Cyclooxygenase-2–Dependent Prostacyclin Formation and Blood Pressure Homeostasis: Targeted Exchange of Cyclooxygenase Isoforms in Mice (2010) (41)
Myeloid cell microsomal prostaglandin E synthase-1 fosters atherogenesis in mice (2014) (41)
Total synthesis of isoprostanes: discovery and quantitation in biological systems. (2004) (41)
Specific Analysis in Plasma and Urine of 2,3-Dinor-5,6-dihydro-isoprostane F2α-III, a Metabolite of Isoprostane F2α-III and an Oxidation Product of γ-Linolenic Acid* (2000) (40)
Sexual dimorphism in body clocks (2020) (39)
Thromboxane receptor-mediated bronchial and hemodynamic responses in ovine endotoxemia. (1988) (39)
Lipid Peroxidation and Platelet Activation in Murine Atherosclerosis (2001) (38)
Cardiovascular biology of microsomal prostaglandin E synthase-1. (2010) (38)
Characterization of a Novel Hemoglobin-Glutathione Adduct That Is Elevated in Diabetic Patients (2001) (38)
The Relationships Among Dose, Effectiveness, and Side Effects (1998) (38)
The human pharmacology of platelet inhibition: pharmacokinetics relevant to drug action. (1985) (38)
Circulating autoantibodies to oxidized cardiolipin correlate with isoprostane F(2alpha)-VI levels and the extent of atherosclerosis in ApoE-deficient mice: modulation by vitamin E. (2001) (36)
Myeloid Cell COX-2 deletion reduces mammary tumor growth through enhanced cytotoxic T-lymphocyte function. (2014) (36)
Differential expression and regulation of cyclooxygenase isozymes in thymic stromal cells. (1999) (36)
Effects of Celecoxib on Prostanoid Biosynthesis and Circulating Angiogenesis Proteins in Familial Adenomatous Polyposis (2012) (35)
Assessment of the therapeutic use of dietary fish oil in atherosclerotic vascular disease and thrombosis. (1989) (34)
Diels−Alder Approach to Isoprostanes. Total Synthesis of iPF2α-V (1998) (34)
Suppression of eicosanoid biosynthesis during coronary angioplasty by fish oil and aspirin. (1991) (34)
Disordered eicosanoid formation in pregnancy-induced hypertension. (1993) (34)
State of the art: Atherosclerosis in a limited edition (1998) (33)
Historical lessons in translational medicine: cyclooxygenase inhibition and P2Y12 antagonism. (2013) (33)
Enhanced monocyte expression of tissue factor by oxidative stress in patients with antiphospholipid antibodies: effect of antioxidant treatment (2003) (33)
Drugs, Industry, and Academia (2008) (31)
Regulation of Cyclooxygenases by Protein Kinase C (1996) (31)
Formation, Signaling and Occurrence of Specialized Pro-Resolving Lipid Mediators—What is the Evidence so far? (2022) (31)
Prothrombinase Acceleration by Oxidatively Damaged Phospholipids* (2000) (31)
A prospective analysis of oxidative stress and liver transplantation1 (2002) (31)
A metabolomic study of adipose tissue in mice with a disruption of the circadian system. (2015) (30)
Oxidized derivatives of ω-3 fatty acids: identification of IPF3α-VI in human urine1 Published, JLR Papers in Press, August 30, 2006. (2006) (30)
Preparation and analysis of deuterium-labeled aspirin: application to pharmacokinetic studies. (1985) (30)
Prostaglandin I2 Promotes the Development of IL-17–Producing γδ T Cells That Associate with the Epithelium during Allergic Lung Inflammation (2011) (30)
Total synthesis of 8,12-iso-iPF3alpha-VI, an EPA-derived isoprostane: stereoselective introduction of the fifth asymmetric center. (2006) (30)
Analysis of HETEs in human whole blood by chiral UHPLC-ECAPCI/HRMS (2018) (30)
Prostacyclin receptor signaling and early embryo development in the mouse. (2007) (29)
Simply read: erythrocytes modulate platelet function. Should we rethink the way we give aspirin? (1997) (29)
CMPF, a Metabolite Formed Upon Prescription Omega-3-Acid Ethyl Ester Supplementation, Prevents and Reverses Steatosis (2017) (29)
The Isoprostanes, a New Class of Natural Products: Synthesis and Biosynthesis (1998) (29)
Molecular Evolution of the Aldo-keto Reductase Gene Superfamily (1998) (28)
Prostaglandin I2 Signaling Drives Th17 Differentiation and Exacerbates Experimental Autoimmune Encephalomyelitis (2012) (28)
A broad-spectrum lipidomics screen of antiinflammatory drug combinations in human blood. (2016) (28)
Inhibition of thromboxane biosynthesis in serum: limitations of the measurement of immunoreactive 6-keto-PGF1 alpha. (1984) (28)
Peripheral clocks and the regulation of cardiovascular and metabolic function. (2005) (27)
Knitting Up the Raveled Sleave of Care* (2013) (27)
The choreography of cyclooxygenases in the kidney. (2002) (27)
Markers of Platelet Activation and Oxidant Stress in Atherothrombotic Disease (1997) (27)
Imprecision: Limitations to Interpretation of a Large Randomized Clinical Trial. (2017) (27)
8-Epi PGF2 alpha: specific analysis of an isoeicosanoid as an index of oxidant stress in vivo. (1996) (26)
Presystemic acetylation of platelets by aspirin: reduction in rate of drug delivery to improve biochemical selectivity for thromboxane A2. (1991) (26)
Symptomatic patent ductus arteriosus following prophylactic indomethacin. A clinical and biochemical appraisal. (1991) (26)
The roles of lipids in SARS-CoV-2 viral replication and the host immune response (2021) (25)
The future of humans as model organisms (2018) (25)
Assessment of the therapeutic use of n-3 fatty acids in vascular disease and thrombosis. (1992) (24)
The Pioglitazone Trek via Human PPAR Gamma: From Discovery to a Medicine at the FDA and Beyond (2018) (23)
Time in Motion: The Molecular Clock Meets the Microbiome (2014) (23)
Academia Europaea Position Paper on Translational Medicine: The Cycle Model for Translating Scientific Results into Community Benefits (2020) (23)
Training Translators for Smart Drug Discovery (2010) (23)
Cold-Induced Browning of Inguinal White Adipose Tissue Is Independent of Adipose Tissue Cyclooxygenase-2. (2018) (23)
Systemic lysis protects against the effects of platelet activation during coronary thrombolysis. (1991) (23)
Prostaglandins: Modulators of Inflammation and Cardiovascular Risk (2004) (23)
The human pharmacology of thrombin inhibition. (1996) (22)
Pharmacokinetics of Tissue‐Type Plasminogen Activator During Acute Myocardial Infarction in Men: Effect of a Prostacyclin Analogue (1992) (22)
Oxidative stress and platelet activation in diabetes mellitus. (1996) (22)
Radioimmunoassay measurement of 2,3-dinor metabolites of prostacyclin and thromboxane in human urine. (1987) (22)
I Prostanoid Receptor–Mediated Inflammatory Pathway Promotes Hepatic Gluconeogenesis Through Activation of PKA and Inhibition of AKT (2014) (22)
Aspirin in Cardiovascular Disease (1988) (22)
ENDOGENOUS PROSTACYCLIN AND THROMBOXANE BIOSYNTHESIS DURING CHRONIC VITAMIN E THERAPY IN MAN (1982) (21)
Twenty-first century phox: not yet ready for widespread screening. (2001) (21)
Bmal1 Deletion in Myeloid Cells Attenuates Atherosclerotic Lesion Development and Restrains Abdominal Aortic Aneurysm Formation in Hyperlipidemic Mice (2020) (21)
Suppression of Eicosanoid Biosynthesis During Coronary Angioplasty by Fish Oil and Aspirin (1991) (21)
Comparative evaluation of RNA-Seq library preparation methods for strand-specificity and low input (2019) (21)
Aspirin reduces the prothrombotic activity of C‐reactive protein (2009) (21)
Clinical pharmacology or translational medicine and therapeutics: reinvent or rebrand and expand? (2007) (21)
Cardiovascular Consequences of Prostanoid I Receptor Deletion in Microsomal Prostaglandin E Synthase-1–Deficient Hyperlipidemic Mice (2016) (19)
Lipocalin-Like Prostaglandin D Synthase but Not Hemopoietic Prostaglandin D Synthase Deletion Causes Hypertension and Accelerates Thrombogenesis in Mice (2018) (19)
The translational therapeutics of prostaglandin inhibition in atherothrombosis (2009) (19)
Cyclooxygenase inhibition abrogates aeroallergen-induced immune tolerance by suppressing prostaglandin I2 receptor signaling. (2014) (19)
Cellular Activation of Thromboxane Receptors a (1994) (19)
TP or not TP: primary mediators in a close runoff? (2000) (19)
Bioactive lipids in antiviral immunity (2021) (18)
Myeloid Cell Hypoxia-Inducible Factors Promote Resolution of Inflammation in Experimental Colitis (2018) (18)
Thymic stromal lymphopoietin induces adipose loss through sebum hypersecretion (2021) (18)
Traditional Nonsteroidal Anti-Inflammatory Drugs and Postmenopausal Hormone Therapy: A Drug–Drug Interaction? (2007) (18)
Protective Role of mPGES-1 (Microsomal Prostaglandin E Synthase-1)–Derived PGE2 (Prostaglandin E2) and the Endothelial EP4 (Prostaglandin E Receptor) in Vascular Responses to Injury (2018) (18)
Measure for Measure: Biomarker standards and transparency (2016) (18)
A microbiome-dependent gut-brain pathway regulates motivation for exercise. (2022) (18)
PGI2 signaling inhibits antigen uptake and increases migration of immature dendritic cells (2013) (17)
Total Synthesis of 17,17,18,18-d4-iPF2α-VI and Quantification of iPF2α-VI in Human Urine by Gas Chromatography/Mass Spectrometry (1998) (17)
Genomic and lipidomic analyses differentiate the compensatory roles of two COX isoforms during systemic inflammation in mice1,2[S] (2017) (17)
Role of Thromboxane Receptor in C-Reactive Protein–Induced Thrombosis (2012) (17)
First total synthesis of isoprostane IPF2α-III (1997) (17)
Smoking-induced vascular disease: a new twist on an old theme. (2001) (16)
Formation of 8-iso-prostaglandin F2 alpha by human platelets. (1995) (16)
Novel indices of oxidant stress in cardiovascular disease: specific analysis of F2-isoprostanes. (1997) (16)
Leukotriene B4 synthesis and neutrophil chemotaxis in chronic granulocytic leukaemia. (1988) (16)
IPF 2 a-I : An index of lipid peroxidation in humans (1998) (16)
Isoprostane activation of the nuclear hormone receptor PPAR. (2002) (16)
Variability in the Analgesic Response to Ibuprofen Is Associated With Cyclooxygenase Activation in Inflammatory Pain (2019) (16)
A prostacyclin analog impairs the response to tissue-type plasminogen activator during coronary thrombolysis: evidence for a pharmacokinetic interaction. (1991) (15)
Excretion of thromboxane A2 and prostacyclin metabolites during treadmill exercise in patients with intermittent claudication. (1988) (15)
Induction of prostacyclin receptor expression in human erythroleukemia cells (1989) (15)
Measurement of thromboxane metabolites by gas chromatography-mass spectrometry. (1990) (15)
Bmal1 deletion in mice facilitates adaptation to disrupted light/dark conditions. (2019) (14)
Accounting for Time: Circadian Rhythms in the Time of COVID-19 (2020) (14)
Functional Characterization of the Ocular Prostaglandin F2α (PGF2α) Receptor (1997) (14)
Platelet-Activating Factor–Induced Reduction in Contact Hypersensitivity Responses Is Mediated by Mast Cells via Cyclooxygenase-2–Dependent Mechanisms (2018) (14)
Gathering intelligence on antiplatelet drugs: the view from 30 000 feet (2002) (14)
Confusion in reperfusion. Problems in the clinical development of antithrombotic drugs. (1997) (14)
Urinary Prostaglandin Metabolites: An Incomplete Reckoning and a Flush to Judgment. (2018) (14)
Prostaglandin F2α Receptor-Dependent Regulation of Prostaglandin Transport (2001) (14)
Aspirin in Hepatocellular Carcinoma (2021) (13)
Perestroika in pharma: evolution or revolution in drug development? (2010) (13)
Analysis of multiple thromboxane metabolites in plasma and urine. (1987) (13)
Specific analysis in plasma and urine of 2,3-dinor-5, 6-dihydro-isoprostane F(2alpha)-III, a metabolite of isoprostane F(2alpha)-III and an oxidation product of gamma-linolenic acid. (2000) (13)
A new method for the preparation of olefins from vicinal diols (1999) (13)
Personalization in practice (2015) (13)
Steroid Hormones and Other Lipid Molecules Involved in Human Reproduction (2019) (13)
Platelet-Specific Deletion of Cyclooxygenase-1 Ameliorates Dextran Sulfate Sodium–Induced Colitis in Mice (2019) (13)
The first total synthesis of iPF4α-VI and its deuterated analog (2002) (13)
Renal metabolism and urinary excretion of thromboxane B2 in the rat. (1989) (12)
Antiplatelet and anticoagulant therapy during coronary thrombolysis. (1991) (12)
Long Term Aspirin in the Prevention of Cardiovascular Disorders (1995) (12)
Isoform-Specific Compensation of Cyclooxygenase (Ptgs) Genes during Implantation and Late-Stage Pregnancy (2018) (12)
Clocks and cardiovascular function. (2015) (12)
Syntheses and identification of the most abundant urinary type VI isoprostanes (1998) (12)
A convenient strategy for the synthesis of β,γ-unsaturated aldehydes and acids. A construction of skipped dienes (1999) (12)
Myeloid Cell 5-Lipoxygenase Activating Protein Modulates the Response to Vascular Injury (2013) (12)
Molecular clocks and the human condition: approaching their characterization in human physiology and disease (2015) (12)
Eicosapentaenoic-acid-derived isoprostanes: synthesis and discovery of two major isoprostanes. (2008) (12)
Differential prostacyclin production by human umbilical vasculature. (1988) (11)
Systemic production of prostacyclin and thromboxane A2 does not correlate with patency of the ductus arteriosus in very low birth weight infants. (1986) (11)
Cyclooxygenase-2, Asymmetric Dimethylarginine, and the Cardiovascular Hazard From Nonsteroidal Anti-Inflammatory Drugs (2018) (11)
Drug development needs a new brand of science (2010) (11)
Guidelines for the design and conduct of human clinical trials on ingestion-time differences – chronopharmacology and chronotherapy – of hypertension medications (2020) (11)
Flipping the cyclooxygenase (Ptgs) genes reveals isoform-specific compensatory functions1,2[S] (2017) (11)
Platelet-dependent vascular occlusion (1994) (10)
Generation of 8-Epiprostaglandin F by Human Monocytes (1996) (10)
Testosterone and thromboxane. Of muscles, mice, and men. (1995) (10)
Loss of circadian protection against influenza infection in adult mice exposed to hyperoxia as neonates (2021) (10)
Effects of fish oil supplementation in the third trimester of pregnancy on prostacyclin and thromboxane production (1993) (10)
A new synthetic approach for 4(S)-hydroxycyclopent-2-enone: a precursor to prostanoid synthesis (2005) (9)
Analysis of isoprostanes (2002) (9)
Bringing PGE2 in from the cold (2015) (9)
Deletion of Microsomal Prostaglandin E Synthase-1 Does Not Alter Ozone-Induced Airway Hyper-Responsiveness (2010) (9)
GCG100649, A Novel Cyclooxygenase‐2 Inhibitor, Exhibits a Drug Disposition Profile in Healthy Volunteers Compatible With High Affinity to Carbonic Anhydrase‐I/II: Preliminary Dose–Exposure Relationships to Define Clinical Development Strategies (2013) (9)
Nonsteroidal anti-inflammatory drugs and glucocorticoids in COVID-19 (2021) (9)
Molecular cloning of the human platelet 12-lipoxygenase. (1990) (9)
Physiological formation of 8-epi-PGF2 alpha in vivo is not affected by cyclooxygenase inhibition. (1995) (8)
iPF2α-III-17,18,19,20-d4: Total synthesis and metabolism (2005) (8)
Oxidized derivatives of omega-3 fatty acids: identification of IPF3 alpha-VI in human urine. (2006) (8)
BIOMEDICINE. Bringing PGE₂ in from the cold. (2015) (8)
Eicosanoids in myocardial ischaemia and injury (1988) (8)
Oral glycoprotein IIb/IIIa antagonism in patients with coronary artery disease. (2001) (8)
Synthesis of iPF2α-V: a new route (1999) (8)
Portal levels of the isoprostane F2 alpha-III, a marker of lipid peroxidation, do not correlate with increased portal pressure in cirrhotic patients. (1998) (8)
The promise and reality of therapeutic discovery from large cohorts. (2020) (7)
Pulmonary Embolism in a Woman Taking Oral Contraceptives and Valdecoxib (2005) (7)
Myeloid Cell mPges-1 Deletion Attenuates Mortality Without Affecting Remodeling After Acute Myocardial Infarction in Mice (2019) (7)
Re-engineering drug discovery and development. (2011) (7)
Cyclooxygenase-2-derived prostacyclin confers atheroprotection on female mice (2005) (7)
Nitecap: An Exploratory Circadian Analysis Web Application (2021) (7)
Cigarettes and the wages of sn-2: oxidized species of PAF in smoking hamsters. (1997) (7)
The molecular, biochemical and human pharmacology of thromboxane A2 in renal disease. (1989) (7)
Hypertensive crisis in prazosin-treated pheochromocytoma. (1984) (6)
Urinary 8-EPI PGF2α: an index of oxidant stress in vivo* (1997) (6)
Formation of 8-iso-Prostaglandin F2α by Human Platelets (1995) (6)
Considerations for the Safe Operation of Schools During the Coronavirus Pandemic (2021) (6)
Chapter 20 Cellular responses to eicosanoids: Molecular biology of eicosanoid receptors (1997) (6)
Cyclooxygenase dependent formation of 8-iso-prostaglandin F2 alpha by human platelets. (1995) (6)
The Molecular Basis of Eicosanoid Action (1993) (6)
Chapter 6 – Prostaglandins and Other Lipid Mediators in Reproductive Medicine (2009) (6)
Time-Dependent Hypotensive Effect of Aspirin in Mice (2018) (6)
Can Intellectual Property Save Drug Development? (2012) (6)
Temporal targets of drug action (2014) (6)
Testing Cardiovascular Drug Safety and Efficacy in Randomized Trials (2014) (6)
Erratum: Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci (American Journal of Human Genetics (2012) 90 (410-425)) (2012) (6)
iPF2α-III metabolism. First total synthesis of 2,3-dinor iPF2α-III, a primary β-oxidation metabolite (2001) (6)
Evolution in translational science: Whither the CTSAs? (2015) (6)
Isoprostanes in the Assessment of Oxidant Stress In Vivo (1999) (6)
Research on COVID-19 through patient-reported data: a survey for observational studies in the COVID-19 pandemic (2020) (6)
Human Platelet Lipidomics: Variance, Visualization, Flux, and Fuel. (2016) (5)
11-Dehydrothromboxane B 2 : A quantitative index of thromboxane A 2 formation in the human circulation ( platelets / atherosclerosis / gas chromatography-mass spectrometry ) (5)
F2 and E2 isoprostanes are ligands for peroxisome proliferator-activated receptors α and γ (1999) (5)
Impact of Time-Restricted Feeding to Late Night on Adaptation to a 6 h Phase Advance of the Light-Dark Cycle in Mice (2021) (5)
Semantic Complexity and Aspirin Resistance (2004) (5)
Follicular Fluid F2-isoprostanes: A Novel Assessment of Oxidative Stress in IVF Patients (2005) (5)
Biosynthesis of P450 products of arachidonic acid in humans: increased formation in cardiovascular disease. (1991) (5)
The Sharing Partnership for Innovative Research in Translation (SPIRiT) Consortium: A Model for Collaboration across CTSA Sites (2013) (5)
Aspirin in the Prevention of Cardiovascular Disease and Cancer. (2021) (5)
Polymerase chain reaction cloning and expression of eicosanoid metabolizing enzymes from blood cells. (1991) (5)
Nanotherapeutic-Directed Approaches to Analgesia. (2021) (5)
Dietary factors in thrombosis and hemostasis: summary and conclusions. (1997) (5)
Monitoring of ROS Oxidative Stress and Cardiovascular Injury: Part I: Basic Mechanisms and In Vivo (2010) (5)
Total Synthesis of a Novel Isoprostane IPF2α‐I and Its Identification in Biological Fluids. (1996) (5)
Moving clinical research in academic medical centres up the value chain (2009) (5)
Total synthesis of 17,17,18,18-d4-iPF2alpha-VI and quantification of iPF2alpha-VI in human urine by gas chromatography/mass spectrometry. (1998) (5)
Activation-dependent internalization of the human prostacyclin receptor. (2002) (4)
Efficient drug approval and monitoring must rely on sound regulatory science (2011) (4)
Not a mouse stirring: deletion of the EP2 and love's labor's lost. (1999) (4)
Therapeutic Aspects of Platelet Pharmacology (1997) (4)
Increased isoprostane biosynthesis in alzheimer's disease: Correlation of a specific non invasive index of lipid peroxidation with disease severity (2000) (4)
CHAPTER 167 – Prostaglandin Mediators (2003) (4)
Platelet andVascular Function During Coronary Thrombolysis WithTissue-Type Plasminogen Activator (1989) (4)
Antiplatelet and anticoagulant drugs in coronary vascular disease. (1992) (4)
(Almost) everything is illuminated: adenosine shines a light on cardioprotection. (2012) (4)
Aspirin in cardiovascular disease; biochemical pharmacology and clinical trials. (1989) (4)
Pharmacological Characterization of the Microsomal Prostaglandin E2 Synthase-1 Inhibitor AF3485 In Vitro and In Vivo (2020) (4)
Regulated expression of the gene coding for the human thromboxane A2 receptor. (1995) (4)
Differential compensation of two cyclooxygenases in renal homeostasis is independent of prostaglandin‐synthetic capacity under basal conditions (2018) (4)
Platelet microRNAs: Novy Mir* or mired in human complexity? (2013) (4)
Cox-2 and beyond: Approaches to prostagland in inhibition in human disease (2003) (3)
CHAPTER 31 – Thromboxane Generation (2007) (3)
Genomic organization of the rat Clock gene and sequence analysis in inbred rat strains. (2006) (3)
Anecdotes from ITMAT: Building Capacity for Translational Science (2013) (3)
Nonsteroidal anti-inflammatory drugs, coxibs, and cardio-renal physiology: a mechanism-based approach. (2002) (3)
Bioactive lipids and atherothrombosis. (2001) (3)
Between a rock and a hard place: how to align our circadian rhythms? (2013) (3)
A new approach to the synthesis of polyunsaturated deuterated isoprostanes: total synthesis of d4-5-epi-8,12-iso-iPF3alpha-VI and d4-8,12-iso-iPF3alpha-VI. (2009) (3)
Prostaglandin F(2alpha) receptor-dependent regulation of prostaglandin transport. (2001) (3)
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY Vitamin E Reduces Monocyte Tissue Factor Expression in Cirrhotic Patients (1999) (3)
Novel Aspects of Aspirin Action (1985) (3)
Response to letters regarding article, "Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin". (2013) (3)
Developmental Expression of Functional Zebrafish Cyclooxygenases (2003) (2)
Presystemic acetylation of platelet cyclooxygenase: Selective inhibition by controlled release-low dose aspirin (1990) (2)
Lipoxygenase, Cyclooxygenase and Leukotriene A4 Hydrolase: Quantitative Polymerase Chain Reaction and Expression Studies (1991) (2)
Prostaglandin E2 Is a Potent Regulator of Vertebrate Hematopoietic Stem Cell Homeostasis. (2006) (2)
Cellular activation by thromboxane A2 and 8-EPI-PGF2 alpha. (1997) (2)
Quantitative Analysis of Eicosanoids by Gas Chromatography-Mass Spectrometry (1989) (2)
Acetaminophen, Nonsteroidal Anti-Inflammatory Drugs, and Hypertension (2022) (2)
Arachidonic Acid Metabolism, Platelets, and Thromboembolic Disease (1992) (2)
Platelets in Thrombotic and Non-thrombotic Disorders: Platelet receptors: prostanoids (2002) (2)
Cyclooxygenase Inhibition and P 2 Y 12 Antagonism (2012) (2)
Prostaglandin I2 Receptor (IP) Signaling Inhibits Lung Type I Interferon Expression by RSV Infection (2013) (2)
Biological clocks: a cardiovascular perspective (2010) (2)
Diels—Alder Approach to Isoprostanes. Total Synthesis of iPF2α‐V. (1999) (2)
Selective COX-2 inhibitors suppress prostacyclin. (2014) (2)
Chapter 150 – Prostaglandin Mediators (2010) (2)
Enzymatic regulation of the prostaglandin response in a human model of inflammation (1996) (2)
The role of Thymic Stromal Lymphopoietin (TSLP) in protection from Type II diabetes (2020) (2)
Erratum: Meta-analysis of dense genecentric association studies reveals common and uncommon variants associated with height ((The American Journal of Human Genetics (2010) 88 (6-18)) (2012) (1)
“What Great Creation” (2012) (1)
Translational therapeutics at the platelet vascular interface. Summary. (2008) (1)
Tempo: an unsupervised Bayesian algorithm for circadian phase inference in single-cell transcriptomics (2022) (1)
Circadian regulation of lung repair and regeneration (2021) (1)
iPF2alpha-III-17,18,19,20-d4: total synthesis and metabolism. (2005) (1)
Non-steroidal anti-inflammatory drugs as a targeted therapy for bone marrow failure in Ghosal Hematodiaphyseal Dysplasia. (2022) (1)
Battle for supremacy: nucleic acid interactions between viruses and cells. (2020) (1)
NSAIDs and cardiovascular risk—Reply (2005) (1)
Abstract 5007: Variability in the Response to Aspirin (2009) (1)
Thromboxane A2/prostacyclin Endoperoxide Receptors. Characterization and Regulation in Human Platelets (1989) (1)
A . Garza Men with Androgenetic Alopecia Inhibits Hair Growth and Is Elevated in Bald Scalp of 2 (2012) (1)
121. Isoprostanes — indices of oxidant stress (1996) (1)
Effects of thromboxane synthase inhibitors on renal function (1988) (1)
Translational therapeutics at the platelet vascular interface. Introduction. (2008) (1)
Factors Associated with Medicine Timing Effects: A Meta-analysis (2021) (1)
Loci influencing blood pressure identified using a cardiovascular gene-centric array (Correction to Ganesh et al. 22 (8): 1663) (2013) (1)
Eicosanoid Dependent and Independent Effects of n-3 Fatty Acids on Platelets and Vascular Function (1992) (1)
Abstract 136: C-Reactive Protein Accelerates Thrombosis by Modulating Arachidonic Acid - Cyclooxygenase Pathways (2007) (1)
Abstract 16834: Assessment of The Pharmacological Response to Aspirin by Quantitation of Platelet Cyclooxygenase Acetylation. (2010) (1)
Oxidant stress in cardiovascular disease: an emerging modality or a disproved theory? (2001) (1)
A Convenient Strategy for the Synthesis of β,γ-Unsaturated Aldehydes and Acids. A Construction of Skipped Dienes. (1999) (1)
Tu-ML5:1 Cardiovascular consequences of cyclooxygenase inhibition; pharmacological targets beyond COX-2 (2006) (0)
Selective Cardiovascular Biology of Microsomal Prostaglandin E Synthase-1 Running title : (2012) (0)
Systemic Eicosanoid and Cytokine Response to Niacin: Implications in HPS2-THRIVE Trial and Beyond†∗ (2014) (0)
A New Method for the Preparation of Olefins from Vicinal Diols. (1999) (0)
A high-throughput chemical genetic screen in zebrafish establishes that prostaglandin E2 is a potent regulator of hematopoietic stem cell formation (2007) (0)
Isoprostanes: Indices of oxidant stress in atherosclerosis (2000) (0)
Erratum: Causal effects of body mass index on cardiometabolic traits and events: A mendelian randomization analysis (American Journal of Human Genetics (2014) 94 (198-208)) (2014) (0)
The obscure targets of desire (2012) (0)
Airways in a Mouse Model of Asthma Th 2 Cells into the + Recruitment of CD 4 Pulmonary Inflammation by Preventing-IP Signaling Blocks Allergic 2 Prostaglandin (2007) (0)
Isoprostane generation in chronic heart failure (1999) (0)
Oxygenated Metabolites of Arachidonic Acid and the Regulation of Platelet-Vascular Interactions* (1985) (0)
Iconographies supplémentaires de l'article : Cyclooxygenase inhibition abrogates aeroallergen-induced immune tolerance by suppressing prostaglandin I 2 receptor signaling (2014) (0)
Sex dependent compensatory mechanisms to preserve blood pressure homeostasis in PGI2 receptor deficient mice (2020) (0)
Abstract 15733: Inducible Postnatal Deletion Of COX-2 Accelerates Atherogenesis In Mice (2011) (0)
Therapeutic strategies to limit thrombosis and modify vascular proliferation (1994) (0)
Variability in the Analgesic Response to Ibuprofen Following Third-Molar Extraction is Associated with Differences in Activation of the Cyclooxygenase Pathway (2018) (0)
Structural characterization of a new glycated hemoglobin Intermediate in the pathway to age crosslink formation (1997) (0)
Interindividual Differences in the Response to Rofecoxib and Celecoxib (2003) (0)
Human CRP and TP Flow Cytometry in Human Umbilical Vein Endothelial Cells After siRNA / CRP Transfection (0)
the Thromboxane A-III Are Mediated via 2-III and iPE α 2 Cardiovascular Responses to the Isoprostanes iPF (2000) (0)
Prostaglandin I2 Receptor (IP) Signaling Inhibits Antigen Uptake but Induce the Ability of Migration on Immature Dendritic Cells (2012) (0)
Activation-dependent internalization of the human prostacyclin receptor (1999) (0)
Erratum: Flipping the cyclooxygenase (Ptgs) genes reveals isoform-specific compensatory functions (2018) (0)
Abstract 613: A Mass Spectrometric Analysis Of Embryonic Zebrafish Proteins (2007) (0)
A More Expensive Aspirin? (2005) (0)
Pharmacological Perturbations of Eicosanoids in vitro and ex vivo in a Novel, Broad‐spectrum, Plasma Lipidomics Assay (2016) (0)
Prostaglandin I2 Receptor (IP) Signaling Inhibits TLR4 Cell Surface Expression and Reduces LPS-induced Lung Inflammation (2011) (0)
Isoprostanes: Chemistry and Biological Significance (1999) (0)
Abstract 349: Measurement of Platelet Cyclooxygenase-1 Acetylation Quantifies Interaction of Nonsteroidal Anti-Inflammatory Drugs with Aspirin in vivo (2013) (0)
Loss of Circadian Protection in Adults Exposed to Neonatal Hyperoxia (2020) (0)
Synthesis of iPF2α-V: A New Route. (1999) (0)
Myeloid cell mPGES-1 mediates inflammatory pain hypersensitivity in mice (2020) (0)
PGI2 inhibits IL-33-induced innate type 2 cytokine responses by natural helper cells (P4343) (2013) (0)
Biomarkers of Oxidant Stress in Vivo: Oxidative Modifications of Lipids, Proteins and DNA (2006) (0)
Abstract 469: mPGES1 deletion and the mechanisms of tumor growth suppression (2015) (0)
Prognostic utility of rhythmic components in 24-hour ambulatory blood pressure monitoring for the risk stratification of chronic kidney disease patients with cardiovascular co-morbidity (2023) (0)
Biological Clocks and the Heart (2010) (0)
Prostaglandin I2 Signaling Exacerbates Experimental Autoimmune Encephalomyelitis (2011) (0)
Biomarkers and exacerbations of asthma and COPD (2011) (0)
COVID-19: lipid disruption is pushing the envelope (2022) (0)
Cell Stimulatory Function of Dendritic Cells Proinflammatory Cytokine Production and T Analogs Inhibit 2 Prostaglandin (2006) (0)
Editorial: Streaming inflammation: From damage to healing and resilience–Volume II (2023) (0)
P410 Effects of Recombinant Human Brain Natriuretic Peptide on a Porcine Model of Acute Pulmonary Hypertension (2010) (0)
Author response: Bidirectional interactions between indomethacin and the murine intestinal microbiota (2015) (0)
OP-22. Localization of isoprostane, 8-epi PGF24aL, in atherosclerotic lesions (1997) (0)
Abstract 449: Circadian Clock Components Regulate the Thrombotic Response to Injury (2007) (0)
The cyclooxygenase-1/mPGES-1/endothelial prostaglandin EP4 receptor pathway constrains myocardial ischemia-reperfusion injury (2019) (0)
plasminogen activator Platelet and vascular function during coronary thrombolysis with tissue- type (2011) (0)
Nucleic Acids Research (2014) (0)
Eicosenoid biosynthesis in acute myocardial infarction and unstable angina (1985) (0)
Monitoring PGD2 production in airway disease (2011) (0)
QUANTITA TIVE ANAL YSIS OF EICOSANOIDS BY GAS CHROMATOGRAPHY (1989) (0)
PIATELETS AND VASCULAR OCCLUSION (2005) (0)
Editorial: Streaming Inflammation: From Damage to Healing and Resilience (2022) (0)
1008-184 The effects of pravastatin and atorvastatin on markers of oxidant stress in vivo (2004) (0)
Systems Pharmacology and Translational Therapeutics (2018) (0)
causes oxidative vascular injury in the lungs Immunotargeting of glucose oxidase to endothelium in vivo (2013) (0)
A Pilot Characterization of the Human Chronobiome (2017) (0)
Biosynthesis of 15-deoxy-D^ -PGJ_2 and the Ligation of PPARγ : 15d-PGJ_2 Is Not the Endogenous Ligand of PPARγ in Vivo (2003) (0)
University of Groningen Gene-centric meta-analysis in 87,736 individuals of European ancestry identifies multiple blood-pressure-related loci Tragante, (2014) (0)
Variant Angina: The Role of Thromboxane A2 with Observations on the Importance of Study Design (1982) (0)
The Current Role of Platelet-Active Drugs in Ischaemic Heart Disease (1991) (0)
Results TP Antagonism , but Not Combined Inhibition of COX-1 and COX-2 , Retards Atherogenesis in DKOs Fed a High-Fat Diet (2005) (0)
Abstract 15738: Cyclooxygenase-2 and Heart Failure With Preserved Ejection Fraction (2019) (0)
Ischemic heart disease and the oxygenated metabolites of arachidonic acid (1985) (0)
Resampling-based read-level normalization of RNA-Seq for differential expression analysis (2016) (0)
Signaling through the PGI2 Receptor Promotes IL-17 Production by CD4 T Cells (2010) (0)
Translational medicine, pharmacology and drug discovery (2018) (0)
Abstract 682: Pharmacological Inhibition of COX and LOX Pathways Leads to Substrate Rediversion: A Novel Plasma Lipidomics Assay to Screen Drugs in Human Blood (2015) (0)
Isoform-Specific Compensation of Cyclooxygenase (Ptgs) Genes during Implantation and Late-Stage Pregnancy (2018) (0)
Insulin Tolerance Test and Hyperinsulinemic-Euglycemic Clamp. (2013) (0)
Abstract B33: Tumor cell-intrinsic EPHA2 suppresses antitumor immunity by regulating PTGS2 (COX-2) in pancreatic adenocarcinoma (2019) (0)
Endothelial Tenascin-X Is Going With the Flow. (2022) (0)
Engineered high-density lipoprotein particles that chaperone bioactive lipid mediators to combat endothelial dysfunction and thromboinflammation (2022) (0)
Author response: Loss of circadian protection against influenza infection in adult mice exposed to hyperoxia as neonates (2021) (0)
Leukotriene B 4 synthesis and neutrophil chemotaxis in chronic granulocytic leukaemia (2005) (0)
Targeted Delivery of mPGES-1 Inhibitors to Macrophages via the Folate Receptor-β for Inflammatory Pain. (2021) (0)
IPF2α-III-M: A NOVEL MARKER OF OXIDANT STRESS IN ORTHOTOPIC LIVER TRANSPLANT (OLT) PATIENTS. (1999) (0)
Modulation of the immune response to SARS-CoV-2 vaccination by NSAIDs. (2023) (0)
Eicosanoids and isoeicosanoids and the cardiovascular system (1999) (0)
SYSTEMIC PRODUCTION OF VASODILATOR EICOSANOIDS IS NOT INCREASED IN INFANTS WITH SYMPTOMATIC PATENT DUCTUS ARTERIOSUS (SPDA) WHO FAIL INDOMETHACIN PROPHYLAXIS (1987) (0)
Leptin, Obesity and Cardiovascular Disease (2003) (0)
The Circadian Biology of Heart Failure (2023) (0)
Distinct vascular effects of celecoxib and rofecoxib in vivo (2015) (0)
Highly selective inhibition of platelet glycoprotein gp iib iiia in the setting of coronary thrombolysis (1992) (0)
Abstract 147: Cell Selective Cardiovascular Biology of mPGES-1 (2012) (0)
iPF2α-III Metabolism. First Total Synthesis of 2,3-Dinor iPF2α-III, a Primary β-Oxidation Metabolite. (2002) (0)
Abstract 13682: 5-Lipoxygenase Activating Protein Attenuates the Response to Vascular Injury (2011) (0)
The role of cyclooxygenases in the cardiovascular system (2002) (0)
Abstract 1132: Antinflammatory role of macrophage Cyclooxygenase 2 derived prostaglandins in vivo (2007) (0)
PGHS-2 Dependent Formation of 8-Epi PGF2α by Human Monocytes (1996) (0)
Circadian disruption in lung fibroblasts enhances NF‐κB activity to exacerbate neutrophil recruitment (2023) (0)
Abstract 5312: Deletion of Microsomal Prostaglandin E2 Synthase-1 Modulates the Response to Vascular Injury in Mice (2009) (0)
Origins of the Anaerobic Gut Lumen: Microbes vs. Chemistry (2017) (0)
Syntheses and Identification of the Most Abundant Urinary Type VI Isoprostanes. (1998) (0)
Transcriptional regulation of, and by, the clock (2005) (0)
The Deficiency of PGI2 Signaling Induces STAT6-independent Allergic Airway Inflammation (2011) (0)
Selective INHIBIT ORS of Cyclooxygenase-2 : A Growing Class of Anti-Inflammatory Drugs (2001) (0)
Oxidative Stress and Cardiovascular Injury Part II: Animal and Human Studies Review: Clinical Cardiology: New Frontiers (2003) (0)
Sex-dependent compensatory mechanisms preserve blood pressure homeostasis in prostacyclin receptor deficient mice. (2021) (0)

This paper list is powered by the following services:

Other Resources About Garret A. FitzGerald

What Schools Are Affiliated With Garret A. FitzGerald?

Garret A. FitzGerald is affiliated with the following schools: